Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZFree Report) in a research note published on Sunday morning. The brokerage issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of NYSE:ENZ opened at $1.08 on Friday. Enzo Biochem has a 12 month low of $0.93 and a 12 month high of $1.50. The company’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.11.

Enzo Biochem Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 15th will be issued a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 37.04%. The ex-dividend date of this dividend is Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after purchasing an additional 11,742 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Enzo Biochem by 2.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after purchasing an additional 64,417 shares during the last quarter. Finally, BBR Partners LLC bought a new position in shares of Enzo Biochem in the 3rd quarter valued at about $112,000. Institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

(Get Free Report)

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.

See Also

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.